A number of new oral drugs are available, with the latest one likely to be available as early as spring

2022-05-24 0 By

Japanese Prime Minister Fumio Kishida said On Feb. 7 that the government will consider granting conditional approval ahead of schedule for the marketing of an oral anti-COVID-19 drug developed by Shionoyi Pharmaceutical Co., according to Xinhua.Kishida told a parliamentary session that the government would approve the oral drug immediately if clinical trials prove it is safe and effective.The People’s Daily Health App combed through the oral drugs approved for marketing, urgent use or about to be marketed, and found that since November 2021, more and more oral drugs have entered the market.First, Merck’s Molnupiravir and Pfizer’s Paxlovid were approved for marketing or emergency use.Following this, VV116, China’s original oral innovative coronavirus drug, was approved for marketing in Uzbekistan not long ago based on excellent clinical trial data.If approved, it will supply 1 million people by the end of March, with plans to ramp up production to 10 million people starting in April.The drug, known as S-217622, is currently in mid-stage clinical trials.In phase II and Iii clinical trials, the novel coronavirus load in asymptomatic and mildly infected patients taking the drug dropped by about 63 to 80 per cent after four days, compared with placebo.The oral drug is also effective against the novel Coronavirus strain of the omicron virus, the company said.”As early as next week, we will apply to advance the launch of the oral drug,” Shionoyoshi President Katsukatsu Tedai said.Shiono plans to add patients with moderate symptoms to the current phase III trial and start a global clinical trial by the end of February.”If the oral drug is approved, Shiono has the capacity to supply one million people by the end of March and plans to significantly ramp up production to supply 10 million people in the next fiscal year starting in April.”New crown for oral administration in our country VV116: is expected to be in the second half of the domestic listed by the Chinese Academy of Sciences, Shanghai institute of drug research institute, Chinese Academy of Sciences, wuhan virus, technical institute of physics and chemistry of the Chinese Academy of Sciences, xinjiang and central Asia drug research and development center, Chinese Academy of Sciences, such as joint research and development of the new champions league VV116 for small molecule drugs, has entered the stage of clinical trials in China.According to CCTV News, preclinical pharmacodynamics studies have shown that VV116 has significant inhibitory activity against novel coronavirus original strain and variant strain, such as Delta virus, in vitro.Researcher at Shanghai institute of materia medica jing-shan shen team and cooperation with scientific research institution by adenovirus mice model on the test found that oral VV116 can reduce virus drops of degrees below the detection limit, can significantly improve lung tissue pathological changes of experimental animal model, a series of preclinical safety evaluation of experiments have shown that better VV116 safety and has no genetic toxicity.The small molecule drug VV116 is promoting the domestic market (expected in the second half of the year).The drug was previously authorized for emergency use in Uzbekistan.On December 23, the US Food and Drug Administration (FDA) authorized Merck’s antiviral drug Monupivir (Molnupiravir) for the treatment of COVID-19, according to the FOOD and Drug Administration.Separately, on December 22, the U.S. Food and Drug Administration (FDA) authorized Pfizer’s COVID-19 antiviral drug Paxlovid, the first ANTIVIRAL COVID-19 pill approved to be taken at home in the United States before a patient becomes sick and hospitalized.Both drugs reduce the risk of hospitalization and death in people who have been diagnosed with COVID-19 virus and are at risk for severe cases of the disease.Recent preclinical evidence suggests that Molnupiravir has antiviral activity against Omicron.Paxlovid was 89 percent effective in preventing hospitalizations and deaths in severely at-risk patients.In addition to the United States, the Israeli Ministry of Health said in a statement on December 26, 2021 that it had approved the emergency use of Paxlovid, an oral treatment for COVID-19 made by Pfizer of the United States.